Anavex Life Sciences Corp (AVXL)

[tredenwater2]

2) To minimize that threat, would Anavex then time the Rett release to a period slightly before the peer review paper on the Alzheimer's P2b/3 trail results, thus establishing a higher value for Anavex?

How about just the opposite? Perhaps they are waiting for the peer review on AD and as soon as that is released all the while they are “cleaning” up RS TLD. In other words proving it works for AD (from a third party) and that it works for Rare diseases such as Rett Syndrome…. and everything in between.

Again folks this is not an Alzheimer’s drug or a Rett Syndrome only drug, this has the potential through genomic testing and AI to PROVE who is responding and by how much leading i to a prophylactic drug trial “system” like a basket trial. This is the “front end taking more time so the back end is faster.” (Paraphrased)

Just a couple more “t’” to cross and a few more “i’s” to dot and we are at the finish line for our first of multiple NDA submittals imo.